Bharat Biotech releases Phase 3 trial data, claims Covaxin is 77.8% effective
Bharat Biotech claimed that its vaccine offered 65.2% protection against the rapidly emerging Delta variant and 93.4% efficacy against severe symptomatic Covid-19.
FollowCovaxin maker Bharat Biotech has declared an overall vaccine efficacy of 77.8% against Covid-19 citing data from the third phase of clinical trials. The data, however, is yet to be peer-reviewed.
Phase three clinical trials of Covaxin were conducted at 25 sites across the country on 130 symptomatic Covid-19 cases, which were reported at least two weeks after the second dose.
The company claimed that its vaccine offered 65.2% protection against the rapidly emerging Delta variant and 93.4% efficacy against severe symptomatic Covid-19.
In a statement on Saturday, the company said that the overall rate of adverse events in Covaxin was lower than that observed in other Covid-19 vaccines.
Covaxin, a whole virus inactivated vaccine against SARS-CoV2, was well tolerated and did not report any safety concerns, it claimed.
Attributing the safety profile of Covaxin to the extensive 20-year safety track record of its Vero cell manufacturing platform, a confident Bharat Biotech said it had not yet sought indemnity for Covaxin from any government.
Dr Krishna Ella, Bharat Biotech chairman and managing director, said that the successful safety and efficacy readouts of Covaxin reinforce the ability of India and developing world countries to focus on innovation and novel product development.
In a post on Twitter, Bharat Biotech co-founder Suchitra Ella said that the company is proud to place India on the global map with scientific conviction, competence and commitment.
She claimed that Covaxin had scored ten world-class publications endorsing its innovation, clinical research, data, safety, efficacy.
Covaxin has received emergency use authorizations in 16 countries including, India, Iran and Mexico.
The company is in discussions with WHO to obtain an emergency-use listing for Covaxin.
